LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

MRK

115.79

-0.22%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

MRK

115.79

-0.22%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

MRK

115.79

-0.22%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

MRK

115.79

-0.22%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

MRK

115.79

-0.22%↓

Начало・Списък с акции・Avidity Biosciences Inc

Avidity Biosciences Inc

Затворен

СекторЗдравеопазване

15.05 4.51

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

15.05

Максимум

15.05

Ключови измерители
By Trading Economics
Приходи	-63M -237M
Продажби	-12M 860K
EPS	-1.27
Марж на печалбата	-27,569.884
Служители	511
EBITDA	-59M -232M

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	-0.1% downside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-9B 2.3B
Предишно отваряне	10.54
Предишно затваряне	15.05

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

25.575 / 32.65 Подкрепа & съпротива

Avidity Biosciences Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

5.03.2026 г., 23:01 ч. UTC

Печалби

Costco Evaluating Possibility of Tariff Refunds as 2Q Revenue Rises - Update

5.03.2026 г., 21:54 ч. UTC

Печалби

Costco Posts Higher 2Q Profit on Rising Sales, Membership Fees

5.03.2026 г., 21:35 ч. UTC

Значими двигатели на пазара

ServiceNow Shares Rise After CEO Says AI Can Add Value to Software

6.03.2026 г., 00:00 ч. UTC

Значими събития в новините

Its Missile Threat Degraded, Iran Is Taking Fewer Shots at More Targets -- WSJ

5.03.2026 г., 23:46 ч. UTC

Пазарно говорене

Nikkei May Decline Amid Concerns About Energy Costs -- Market Talk

5.03.2026 г., 23:33 ч. UTC

Пазарно говорене

Gold Edges Higher on Possible Technical Recovery -- Market Talk

5.03.2026 г., 23:27 ч. UTC

Пазарно говорене

Middle East Fighting Will Prompt RBA to Delay Hike -- Market Talk

5.03.2026 г., 22:54 ч. UTC

Пазарно говорене

Печалби

Costco Sold a $150,000 Diamond Ring in 2Q -- Market Talk

5.03.2026 г., 22:50 ч. UTC

Пазарно говорене

Woodside Has More Exposure to Rising Gas Prices Than Santos -- Market Talk

5.03.2026 г., 22:48 ч. UTC

Печалби

Nike Reports $300 Million Pretax Charge Related to Job Cuts -- Barrons.com

5.03.2026 г., 22:46 ч. UTC

Печалби

Costco Evaluating Possibility of Tariff Refunds as 2Q Revenue Rises -- Update

5.03.2026 г., 22:44 ч. UTC

Печалби

Costco Earnings Beat Expectations as Membership Model Shines -- Barrons.com

5.03.2026 г., 21:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

5.03.2026 г., 21:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

5.03.2026 г., 21:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

5.03.2026 г., 21:35 ч. UTC

Печалби

Marvell Earnings Beat Estimates on 'Robust' AI Demand. The Stock Jumps. -- Barrons.com

5.03.2026 г., 21:32 ч. UTC

Печалби

Costco Earnings Beat Expectations as Membership Model Shines -- Barrons.com

5.03.2026 г., 21:26 ч. UTC

Печалби

These Stocks Are Today's Movers: Broadcom, Trade Desk, Berkshire Hathaway, Rigetti, Corning, Ciena, Expedia, and More -- Barrons.com

5.03.2026 г., 21:24 ч. UTC

Печалби

Costco February Digitally-Enabled Sales Ex-Changes in Gas and Foreign Exchange Rose 20.8% >COST

5.03.2026 г., 21:23 ч. UTC

Печалби

Costco February Same-Store Sales Ex-Changes in Gas and Foreign Exchange Rose 7% >COST

5.03.2026 г., 21:22 ч. UTC

Печалби

Costco 2Q Same-Store Sales Ex-Changes in Gas and Foreign Rose 6.7% >COST

5.03.2026 г., 21:21 ч. UTC

Печалби

Costco February Digitally-Enabled Sales Rose 21.8% >COST

5.03.2026 г., 21:21 ч. UTC

Печалби

Costco Total Co Comparable Sales for February Rose 7.9% >COST

5.03.2026 г., 21:20 ч. UTC

Печалби

Costco February Net Sales Were $21.69 B >COST

5.03.2026 г., 21:20 ч. UTC

Печалби

Marvell Earnings Beat Estimates on 'Robust' AI Demand. The Stock Jumps. -- Barrons.com

5.03.2026 г., 21:20 ч. UTC

Печалби

Costco Same-Store Sales Ex-Changes in Gas and Foreign Rose 6.7% >COST

5.03.2026 г., 21:19 ч. UTC

Печалби

Costco 2Q Digitally-Enabled Sales Ex-Changes in Gas and Foreign Exchange Rose 21.7% >COST

5.03.2026 г., 21:18 ч. UTC

Печалби

Costco 2Q Digitally-Enabled Sales Rose 22.6% >COST

5.03.2026 г., 21:18 ч. UTC

Печалби

Costco 2Q Same-Store Sales Up 7.4% >COST

5.03.2026 г., 21:15 ч. UTC

Печалби

Costco 2Q EPS $4.58 >COST

Сравнение с други в отрасъла

Ценова промяна

Avidity Biosciences Inc Прогноза

Ценова цел

By TipRanks

-0.1% надолу

12-месечна прогноза

Среден 72.75 USD -0.1%

Висок 75 USD

Нисък 72 USD

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за Avidity Biosciences Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

4 ratings

Купи

Задържане

Продай

Според 4 анализатори, дали борсови рейтинги на Avidity Biosciences Inc през последните 3 месеца.

Техническа оценка

By Trading Central

25.575 / 32.65Подкрепа & съпротива

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Recent bearish events outweigh bullish events.

Финанси

Относно Avidity Biosciences Inc

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.